InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
InspireMD Inc. (NSPR)
NASDAQ:AMEX Investor Relations:
inspiremd.com/en/investors/investor-relations
Company Research
Source: GlobeNewswire
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day or one-year neurological complications TEL AVIV, Israel, Nov. 26, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today reported on updated registry study data presented at the 2019 VEITH Symposium, which was held November 19-23 in New York City. “The annual VEITH symposium is among the most prestigious gatherings of vascular surgeons, cardiologists, cardiac surgeons and vascular medicine specialists. We are pleased to once again see that the data presented at the symposium further demonstrates the clinical advantages of CGuard™ EPS,” said Jam
Show less
Read more
Impact Snapshot
Event Time:
NSPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NSPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NSPR alerts
High impacting InspireMD Inc. news events
Weekly update
A roundup of the hottest topics
NSPR
News
- InspireMD, Inc. (NYSE: NSPR) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
- InspireMD Inc (NSPR) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Rising Costs and ... [Yahoo! Finance]Yahoo! Finance
- InspireMD Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings [Yahoo! Finance]Yahoo! Finance
NSPR
Earnings
- 11/12/24 - Beat
NSPR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SCHEDULE
- 11/12/24 - Form 10-Q
- NSPR's page on the SEC website